As of 31 Dec 2025, 45 institutional investors reported holding $320,921,624 in principal (par value) of ALNYLAM PHARMACEUTICALS INC - NOTE 1.000% 9/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $320,921,624 | $472,661,567 | -$80,528,515 | 147.05% | 45 |
| 2025 Q3 | $377,271,743 | $620,397,099 | -$747,537,261 | 164.35% | 44 |
| 2025 Q2 | $981,078,530 | $1,277,359,156 | -$13,039,270 | 129.9% | 70 |
| 2025 Q1 | $969,592,530 | $1,118,503,734 | +$88,986,381 | 115.38% | 69 |
| 2024 Q4 | $922,607,020 | $983,794,436 | +$11,008,622 | 106.55% | 67 |
| 2024 Q3 | $904,121,020 | $1,058,866,946 | -$27,889,010 | 117.0% | 58 |
| 2024 Q2 | $905,137,980 | $978,913,598 | -$105,053,955 | 107.81% | 65 |
| 2024 Q1 | $1,012,540,800 | $955,060,150 | +$37,637,775 | 94.06% | 69 |
| 2023 Q4 | $979,138,050 | $970,383,077 | +$19,195,483 | 98.75% | 67 |
| 2023 Q3 | $976,407,604 | $910,151,140 | +$910,150,772 | 92.75% | 55 |